HIV 1 Integrase (EC 2.7.7.) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘HIV 1 Integrase (EC 2.7.7.) – Pipeline Review, H2 2016’, provides in depth analysis on HIV 1 Integrase (EC 2.7.7.) targeted pipeline therapeutics.

The report provides comprehensive information on the HIV 1 Integrase (EC 2.7.7.) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in HIV 1 Integrase (EC 2.7.7.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for HIV 1 Integrase (EC 2.7.7.)

The report reviews HIV 1 Integrase (EC 2.7.7.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in HIV 1 Integrase (EC 2.7.7.) targeted therapeutics and enlists all their major and minor projects

The report assesses HIV 1 Integrase (EC 2.7.7.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to HIV 1 Integrase (EC 2.7.7.) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for HIV 1 Integrase (EC 2.7.7.)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding HIV 1 Integrase (EC 2.7.7.) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Critical Outcome Technologies Inc

Gilead Sciences Inc

Merck & Co Inc

TGV-Laboratories

ViiV Healthcare Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

HIV 1 Integrase (EC

2.7.7.) Overview 7

Therapeutics Development 8

HIV 1 Integrase (EC

2.7.7.) - Products under Development by Stage of Development 8

HIV 1 Integrase (EC

2.7.7.) - Products under Development by Therapy Area 9

HIV 1 Integrase (EC

2.7.7.) - Products under Development by Indication 10

HIV 1 Integrase (EC

2.7.7.) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

HIV 1 Integrase (EC

2.7.7.) - Products under Development by Companies 13

HIV 1 Integrase (EC

2.7.7.) - Products under Development by Universities/Institutes 15

HIV 1 Integrase (EC

2.7.7.) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

HIV 1 Integrase (EC

2.7.7.) - Companies Involved in Therapeutics Development 23

Critical Outcome Technologies Inc 23

Gilead Sciences Inc 24

Merck & Co Inc 25

TGV-Laboratories 26

ViiV Healthcare Ltd 27

HIV 1 Integrase (EC

2.7.7.) - Drug Profiles 28

(bictegravir sodium +emtricitabine + tenofovir alafenamide) - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

(dolutegravir sodium + rilpivirine hydrochloride) - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Antisense RNAi Oligonucleotide to Inhibit HIV-I Integrase for HIV - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

cabotegravir sodium - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

cabotegravir sodium + rilpivirine hydrochloride - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

elvitegravir - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

M-522 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

M-532 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

MK-2048 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecule to Inhibit HIV-1 Integrase for HIV infection - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Small Molecule to Inhibit Integrase for HIV - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Small Molecules to Inhibit HIV-1 Integrase for HIV-1 Infection - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

T-169 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

HIV 1 Integrase (EC

2.7.7.) - Dormant Projects 46

HIV 1 Integrase (EC

2.7.7.) - Discontinued Products 47

HIV 1 Integrase (EC

2.7.7.) - Featured News & Press Releases 48

Nov 18, 2016: ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen 48

Jul 26, 2016: SMILE Trial Launch - investigating a potentially lower toxicity, simplified treatment regimen for HIV infected children 48

Feb 24, 2016: ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir 49

Feb 23, 2016: ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment 50

Nov 03, 2015: ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy 51

May 06, 2015: ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy 52

Apr 15, 2015: Critical Outcome Technologies Receives First U.S. Patent For Next Generation HIV Treatment 52

Jan 15, 2015: Long-acting drug effectively prevents HIV-like infection in monkeys 53

Apr 21, 2014: Gilead Sciences’ New Drug Applications for Elvitegravir for HIV Therapy Accepted by U.S. FDA 54

Nov 18, 2013: European Commission Approves Gilead’s Vitekta, an Integrase Inhibitor for the Treatment of HIV-1 Infection 54

Sep 19, 2013: Gilead Sciences Receives CHMP Positive Opinion For Vitekta For Treatment Of Human Immunodeficiency Virus-1 Infection In Adults 55

Jul 03, 2013: Monthly Injections With GSK And J&J's Combination Therapy Sustained Drug Levels In Blood To Control HIV, Study Shows 56

Apr 29, 2013: Gilead Sciences Receives Complete Response Letter From FDA For Elvitegravir 56

May 20, 2010: Critical Outcome Technologies Inc. Discovers Novel Scaffolds For Inhibiting HIV Integrase 57

Apr 13, 2010: Critical Outcome Technologies Inc. Provides Update On HIV-1 Integrase Co-Development Program 57

Appendix 59

Methodology 59

Coverage 59

Secondary Research 59

Primary Research 59

Expert Panel Validation 59

Contact Us 59

Disclaimer 60

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Critical Outcome Technologies Inc, H2 2016 23

Pipeline by Gilead Sciences Inc, H2 2016 24

Pipeline by Merck & Co Inc, H2 2016 25

Pipeline by TGV-Laboratories, H2 2016 26

Pipeline by ViiV Healthcare Ltd, H2 2016 27

Dormant Projects, H2 2016 46

Discontinued Products, H2 2016 47

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared